शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
ARTEMISMEDNSEArtemis Medicare Services Limited· Healthcare ServicesHighPositive
Announced Mon, 12 May, 2025 · 18:10 IST

Artemis Medicare Services Limited has informed the Exchange that Board of Directors at its meeting held on May 12, 2025, recommended Final Dividend of Rs. 0.45 per equity share.

Pat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing

ARTEMISMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.2%Reaction day
₹255.00
prior close
₹250.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.6%-3.8% vs market
Hospital peers, median of 18sector+0.9%-3.1% vs sector

On the reaction day the stock moved 3.8 pts less than Nifty Microcap 250 and 3.1 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-2.6
10m
-1.3
15m
-0.1
30m
-0.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.2+1.6-3.8+0.9-3.1
Next day
-2.2+3.3-5.5+1.6-3.8
2d
-2.2+4.3-6.5+2.5-4.8
3d
-4.3+5.1-9.4+2.1-6.4
4d
-2.6+6.4-9.0+1.3-3.9
5d
+0.3+5.2-5.0+0.6-0.4
1w
-2.4+5.9-8.3+2.5-4.9
15d
+5.1+8.0-2.9-1.1+6.1
1m
+2.0+9.8-7.8+1.9+0.1
2m
-2.3+11.8-14.0+9.7-11.9
3m
-5.0+7.2-12.2+13.0-18.0
UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 18Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Artemis Medicare Services reported strong FY25 standalone results with revenue from operations rising about 8% to Rs. 913.26 crore (from Rs. 845.23 crore) and net profit jumping roughly 70% to Rs. 83.46 crore (from Rs. 49.15 crore). EBITDA margin expanded from about 16% to 20% YoY, driving most of the profit growth. For Q4 FY25, revenue grew about 8% to Rs. 234.80 crore while net profit surged about 67% to Rs. 23.20 crore. The Board recommended a final dividend of Rs. 0.45 per equity share (45% on the Re. 1 face value), subject to shareholder approval. Auditor T R Chadha & Co LLP issued an unmodified (clean) opinion on both standalone and consolidated results. Other decisions included the appointment of Mr. Sunam Sarkar as a Non-Executive Director, the resignation of Dr. Nirmal Kumar Ganguly, the exit of Ms. Deepa Gopalan Wadhwa on completion of her independent director term, and the appointment of DMK Associates as secretarial auditor for five years (FY26–FY30). The company had also raised Rs. 330 crore via Compulsorily Convertible Debentures to IFC, which is reflected in sharply higher bank balances.

Likely market impact

The strong profit growth and EBITDA margin expansion are positive signals for shareholders, and the 45% dividend reflects healthy cash generation. The balance sheet is much stronger post the IFC CCD infusion, though conversion of those CCDs into equity could lead to future dilution. The board turnover is routine and unlikely to materially affect operations.